Not sure how this is as a like for like basis for pillar lll but J&J signed a deal with argenix, for their AML drug in 2018.
300m upfront and 200m equity, at phase I. Milestones to reach 1.8b. this is not a buyout but a partnership.
https://endpts.com/jj-fronts-new-cancer-drug-pact-with-500m-in-cash-for-argenxs-aml-antibody/
can anyone compare this to bisantrene for AML?
RACE Oncology Peer Analysis, page-28
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |